Ab Initio provides GMP pMDIs for InhaleRX Phase 1 clinical trial.

Ab Initio is pleased to have supported InhaleRX as its chosen contract manufacturing organisation (CMO) for a Phase 1 clinical trial of a dronabinol (THC  based) inhalation product that addresses the symptoms of break-through or acute pain. Ab Initio successfully transferred production methodology from a leading UK R&D company specialising in pressurised metered dose formulation, manufactured devices in its state-of the-art GMP facility in Sydney and released for InhaleRX’s clinical trial. You can read InhaleRX full ASX press release here

Ab Initio is an Australian based pharmaceutical GMP company that specialises in production of new therapies for clinical trials. Ab Initio holds a TGA licence for the manufacture, testing, packaging, and release of inhalation products, including nasal, dry powder and pressurised metered dose inhalers. Ab Initio can additionally handle potent NCEs, scheduled medicines as well as produce conventional oral and topical dosage forms.

COO and Head of Quality, Dr Will Glover said “Ab Initio is uniquely placed to offer clients GMP manufacturing, and testing, of inhalation products that is not available elsewhere in the region. By supporting InhaleRX’s with formulations, manufactured in a TGA licenced facility to international standards, we can ensure the highest quality products enter critical trials”.

To learn more about Ab Initio’s capabilities visit www.ab-initio-pharma.com